Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

The aim of the study was to determine the maximum tolerated dose (MTD) and safety of the combination of bortezomib and cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) as first-line therapy in advanced, aggressive T-cell lymphoma. Patients received increasing doses of bortezomib o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lee, J., Suh, C., Kang, H. J., Ryoo, B.-Y., Huh, J., Ko, Y. H., Eom, H.-S., Kim, K., Park, K., Kim, W. S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2008
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2733119/
https://ncbi.nlm.nih.gov/pubmed/18689866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdn431
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi